Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesIncannex Healthcare Inc.

Incannex Healthcare Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.975 USD -0.04 ( 1.74%)
Last update at 2026-11-11T21:17:00Z
VOLUME
66076
Market Cap
41.28M

Momentum Score

…

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.96
Low
2.10
High
52 Week Price Range
2.49
Low
20.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Incannex Healthcare Ltd (NASDAQ: IXHL) is a clinical-stage Australian pharmaceutical company developing cannabinoid-based and combination therapeutics for respiratory and central nervous system conditions. Long-term growth drivers include clinical trial progress, intellectual property development, regulatory approvals, and partnerships or licensing that could support commercialization. Investors may find exposure to novel therapeutic approaches and a diversified development pipeline attractive if programs advance successfully.

Material risks include clinical trial or regulatory failure, limited or no product revenue with likely future financing and dilution, and competitive and market-access challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.01
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-117.17%
Net Debt
-14.78M
ROCE
-176.70%
Diluted EPS TTM
-16.62

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -48.64M -18.43M -19.98M -14.90M -8.16M
Net income -46.88M -18.46M -19.98M -15.03M -8.16M
Selling general administrative 12.74M 23.98M 10.01M 7.43M 3.44M
Selling and marketing expenses 0.39M 1.58M 1.85M 2.75M 1.14M
Gross profit -0.16M 0.01M 0.00M -0.01M 0.99M
Reconciled depreciation - 0.10M 0.13M 0.00M -
Ebit -23.79M -27.86M -20.34M -14.78M -8.24M
Ebitda -23.54M -27.70M -20.21M -14.64M -8.24M
Depreciation and amortization 0.25M 0.15M 0.13M 0.13M 0.08M
Operating income -23.79M -30.04M -20.34M -14.78M -8.24M
Other operating expenses 23.88M 30.05M 20.34M 14.78M 10.14M
Interest expense 0.30M - - 0.01M 0.00M
Tax provision - 0.03M 0.00M 0.00M 0.00M
Interest income - 0.21M 0.36M 0.01M 0.00M
Net interest income - 0.21M 0.36M 0.01M 0.00M
Income tax expense -1.76M 0.03M - 0.12M -0.00M
Total revenue 0.09M 0.01M 0.00M 0.00M 1.90M
Total operating expenses 23.63M 30.05M 20.34M 14.77M 9.22M
Cost of revenue 0.25M 0.10M 0.00M 0.01M 0.91M
Total other income expense net -24.85M 0.18M 0.36M -0.13M 0.08M
Net income from continuing ops - -18.46M -19.98M -21.67M -8.16M
Net income applicable to common shares - - -19.98M -14.90M -11.37M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 20.45M 17.05M 88.59M 37.88M 9.33M
Intangible assets - - 52.72M - -
Other current assets 0.30M 0.33M 1.04M 0.06M 0.04M
Total liab 7.06M 5.83M 4.46M 2.01M 0.76M
Total stockholder equity 13.39M 11.22M 84.13M 35.87M 8.57M
Other current liab 0.76M 4.84M 0.97M 0.71M 0.52M
Common stock 0.02M 0.00M 150.84M 86.59M 45.94M
Capital stock - 0.00M 150.84M 125.87M 45.94M
Retained earnings -157.56M -110.67M -78.77M -58.79M -40.68M
Cash 15.04M 5.86M 33.36M 37.50M 9.12M
Total current liabilities 6.98M 5.62M 3.85M 2.01M 0.76M
Current deferred revenue - 0.09M - - -
Net debt -14.78M -5.49M -32.58M -37.50M -9.12M
Short term debt 0.18M 0.16M 0.17M - -
Short long term debt total 0.26M 0.37M 0.79M - -
Other stockholder equity 174.05M 125.22M 12.06M 8.08M -
Property plant equipment - - 1.19M - -
Total current assets 19.96M 16.20M 34.69M 37.88M 9.33M
Net tangible assets - - 31.41M 35.87M 8.57M
Net receivables 4.63M 10.02M 0.39M 0.32M 0.17M
Inventory - -10.02M -0.10M - -
Accounts payable 6.07M 0.53M 2.71M 1.30M 0.23M
Accumulated other comprehensive income -3.12M -3.33M 12.06M - 3.32M
Non current assets total 0.48M 0.84M 53.90M 0.00M 0.00M
Capital lease obligations - 0.37M 0.79M - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.28M -0.48M 0.00M 0.03M
Change to liabilities - - 1.56M 1.11M -0.29M
Total cashflows from investing activities -0.01M -0.28M -0.48M -0.48M 0.03M
Net borrowings - - -0.05M -0.05M -0.05M
Total cash from financing activities 21.40M 0.00M 0.01M 41.18M 12.40M
Change to operating activities - - -0.85M 0.21M -0.10M
Net income -46.88M -18.46M -19.98M -14.90M -8.16M
Change in cash 9.18M -16.26M -0.00M 28.38M 5.52M
Begin period cash flow 5.86M 22.12M 0.04M 9.12M 3.60M
End period cash flow 15.04M 5.86M 0.03M 37.50M 9.12M
Total cash from operating activities -12.51M -15.85M -0.02M -12.81M -6.91M
Issuance of capital stock - 0.00M 0.01M 59.87M 12.40M
Depreciation 0.25M 0.10M 0.13M 0.13M 0.13M
Dividends paid - - 0.00M 0.00M -
Change to inventory - - - 0.00M 0.18M
Change to account receivables 5.58M -9.84M 0.01M -0.09M 0.21M
Other cashflows from financing activities -24.77M -0.28M 0.05M 0.03M 0.03M
Change to netincome - - 3.19M 0.87M 4.46M
Capital expenditures 0.01M 0.28M 0.00M 0.48M 0.48M
Change in working capital 6.78M -9.47M 0.72M 1.23M -
Stock based compensation 2.61M 8.93M 3.19M 1.46M -
Other non cash items 24.74M 3.05M 15.92M -0.59M 8.16M
Free cash flow -12.52M -16.12M -0.02M -12.81M -6.91M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IXHL
Incannex Healthcare Inc.		 -0.04
1.74%		 1.98 - 3.78 7764.11 0.55 388.53 -5.13
MKKGY
Merck KGaA ADR		 0.13
0.39%		 33.80 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 169.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.84 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Incannex Healthcare Inc.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

8 Century Circuit, Sydney, NSW, Australia, 2153

61 4 0984 0786

https://www.incannex.com

12

Name Title Year Born
Mr. Joel Bradley Latham MD, CEO & Exec. Director 1990
Mr. Madhukar Bhalla CFO & Company Sec. 1959
Mr. Lekhram Changoer M.Sc. Chief Technical Officer 1967
Dr. Mark Bleackley Chief Scientific Officer, Head of Programs & Member of the Advisory Board NA
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Exec. Officer of IncannexTM NA
Ms. Rosemarie Walsh VP of Clinical Operations & Member of the Advisory Board NA
Mr. Joseph Swan Head of Fin. NA
Mr. Joel Bradley Latham MD, CEO & Executive Director 1990
Mr. Joseph Swan CFO, Treasurer & Secretary 1992
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Executive Officer of IncannexTM NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…